Literature DB >> 23718715

Angiotensin II type 1 receptor blockade restores angiotensin-(1-7)-induced coronary vasodilation in hypertrophic rat hearts.

Álvaro P S Souza1, Deny B S Sobrinho, Jônathas F Q Almeida, Gisele M M Alves, Larissa M Macedo, Juliana E Porto, Eneida F Vêncio, Diego B Colugnati, Robson A S Santos, Anderson J Ferreira, Elizabeth P Mendes, Carlos H Castro.   

Abstract

The aim of the present study was to investigate the coronary effects of Ang-(1-7) [angiotensin-(1-7)] in hypertrophic rat hearts. Heart hypertrophy was induced by abdominal aorta CoA (coarctation). Ang-(1-7) and AVE 0991, a non-peptide Mas-receptor agonist, at picomolar concentration, induced a significant vasodilation in hearts from sham-operated rats. These effects were blocked by the Mas receptor antagonist A-779. Pre-treatment with L-NAME (N(G)-nitro-L-arginine methyl ester) or ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinozalin-1-one) [NOS (NO synthase) and soluble guanylate cyclase inhibitors respectively] also abolished the effect of Ang-(1-7) in control hearts. The coronary vasodilation produced by Ang-(1-7) and AVE 0991 was completely blunted in hypertrophic hearts. Chronic oral administration of losartan in CoA rats restored the coronary vasodilation effect of Ang-(1-7). This effect was blocked by A-779 and AT2 receptor (angiotensin II type 2 receptor) antagonist PD123319. Acute pre-incubation with losartan also restored the Ang-(1-7)-induced, but not BK (bradykinin)-induced, coronary vasodilation in hypertrophic hearts. This effect was inhibited by A-779, PD123319 and L-NAME. Chronic treatment with losartan did not change the protein expression of Mas and AT2 receptor and ACE (angiotensin-converting enzyme) and ACE2 in coronary arteries from CoA rats, but induced a slight increase in AT2 receptor in aorta of these animals. Ang-(1-7)-induced relaxation in aortas from sham-operated rats was absent in aortas from CoA rats. In vitro pre-treatment with losartan restored the Ang-(1-7)-induced relaxation in aortic rings of CoA rats, which was blocked by the Mas antagonist A-779 and L-NAME. These data demonstrate that Mas is strongly involved in coronary vasodilation and that AT1 receptor (angiotensin II type 1 receptor) blockade potentiates the vasodilatory effects of Ang-(1-7) in the coronary beds of pressure-overloaded rat hearts through NO-related AT2- and Mas-receptor-dependent mechanisms. These data suggest the association of Ang-(1-7) and AT1 receptor antagonists as a potential therapeutic avenue for coronary artery diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23718715     DOI: 10.1042/CS20120519

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  16 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

2.  Angiotensin-(1-7): Translational Avenues in Cardiovascular Control.

Authors:  Daniela Medina; Amy C Arnold
Journal:  Am J Hypertens       Date:  2019-11-15       Impact factor: 2.689

Review 3.  The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).

Authors:  Robson Augusto Souza Santos; Walkyria Oliveira Sampaio; Andreia C Alzamora; Daisy Motta-Santos; Natalia Alenina; Michael Bader; Maria Jose Campagnole-Santos
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

Review 4.  Angiotensin-(1-7) and Alamandine on Experimental Models of Hypertension and Atherosclerosis.

Authors:  Fernando Pedro de Souza-Neto; Melissa Carvalho Santuchi; Mario de Morais E Silva; Maria José Campagnole-Santos; Rafaela Fernandes da Silva
Journal:  Curr Hypertens Rep       Date:  2018-03-14       Impact factor: 5.369

5.  Vascular Actions of Angiotensin 1-7 in the Human Microcirculation: Novel Role for Telomerase.

Authors:  Matthew J Durand; Natalya S Zinkevich; Michael Riedel; David D Gutterman; Victoria L Nasci; Valerie K Salato; John B Hijjawi; Charles F Reuben; Paula E North; Andreas M Beyer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-04-14       Impact factor: 8.311

6.  Mechanisms of Mas1 Receptor-Mediated Signaling in the Vascular Endothelium.

Authors:  Brian R Hoffmann; Timothy J Stodola; Jordan R Wagner; Daniela N Didier; Eric C Exner; Julian H Lombard; Andrew S Greene
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-01-12       Impact factor: 8.311

7.  Cardiovascular effects of small peptides of the renin angiotensin system.

Authors:  Patrícia L Moraes; Lucas M Kangussu; Luiz Gonzaga da Silva; Carlos H Castro; Robson A S Santos; Anderson J Ferreira
Journal:  Physiol Rep       Date:  2017-11

8.  Stimulation of the ACE2/Ang-(1-7)/Mas axis in hypertensive pregnant rats attenuates cardiovascular dysfunction in adult male offspring.

Authors:  Amanda S M Bessa; Érika F Jesus; Allancer D C Nunes; Carolina N R Pontes; Ismaley S Lacerda; Jaqueline M Costa; Elisângela J Souza; Ruy S Lino-Júnior; Manoel F Biancardi; Fernanda C A Dos Santos; Gustavo R Pedrino; Diego B Colugnati; Renata Mazaro-Costa; Elizabeth P Mendes; Carlos H Castro
Journal:  Hypertens Res       Date:  2019-09-10       Impact factor: 3.872

9.  Olmesartan medoxomil reverses glomerulosclerosis in renal tissue induced by myocardial infarction without changes in renal function.

Authors:  Xiao-Mei Lu; Yu-Nan Jin; Ling Ma
Journal:  Exp Ther Med       Date:  2014-04-25       Impact factor: 2.447

10.  Amelioration of cardiac function and activation of anti-inflammatory vasoactive peptides expression in the rat myocardium by low level laser therapy.

Authors:  Martha Trindade Manchini; Andrey Jorge Serra; Regiane dos Santos Feliciano; Eduardo Tadeu Santana; Ednei Luis Antônio; Paulo de Tarso Camillo de Carvalho; Jairo Montemor; Renato Oliveira Crajoinas; Adriana Castello Costa Girardi; Paulo José Ferreira Tucci; José Antônio Silva
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.